No specific funding for this study was applied. Declarations Conflict of interestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be seen as a potential conflict of interest. Ethics approvalThe study was exempt from ethical review while no patients or BFH772 study subjects were involved. than 50% of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroquine (94.2%), anakinra (79.2%) or canakinumab (72.5%), or tocilizumab (69.8%). Long-term corticosteroids would be reduced by 26.9% (?2?mg/kg/day), respectively, with only 5.8% of respondents voting to CYFIP1 discontinue the therapy. Conversely, more than 75% of respondents would refrain from administering cyclophosphamide and anti-CD20-antibodies. As evidence on management of pediatric COVID-19 is incomplete, continuous and critical expert opinion and knowledge exchange is helpful. Supplementary Information The online version contains supplementary material available at 10.1007/s00296-021-04824-4. Keywords: COVID-19, SARS-CoV-2, Children, Pediatric rheumatology, Autoimmune disease, Inflammation, Treatment, Opinion poll Introduction The newly emerged coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the infectious pathogen causing COVID-19 (corona virus disease 2019), a pandemic that poses a threat to millions of lives and, therefore, a challenge to healthcare providers of all medical specialities. It became apparent that the shared expertise of rheumatologists BFH772 and clinical immunologists is critical in the treatment of COVID-19 patients, as a significant proportion of adult and few pediatric patients develop hyperinflammatory disease [1C7]. While the course of COVID-19 in healthy children is usually asymptomatic or mild when compared to adults [8, 9], a hyperinflammation syndrome (pediatric inflammatory multisystem syndrome: PIMS or MIS-C: multisystem inflammatory syndrome in children) timely associated with SARS-CoV-2 has been described in a subset of pediatric patients in Europe and North America [2, 10C13]. Although patients with pediatric autoimmune/inflammatory disease (Help) could be more vunerable to trojan infections in comparison with age-matched healthful cohorts, and Help patients-receiving immunomodulatory or immunosuppressive therapy are believed to become more prone towards viral and bacterial attacks [14, 15], there is absolutely no reliable proof to suggest an increased threat of SARS-CoV-2 an infection or more serious disease in those sufferers [4, 16C21]. Whether immune system insufficiency and/or immunomodulating treatment might prevent serious problems such as for example PIMS-TS/MIS-C remains to be unclear [22] also. Hence, in the lack of potential research in huge cohorts, administration of patients-receiving immunosuppression/modulation continues to be a particular problem, as data are primary and relatively conflicting concerning whether or which kind of immunomodulation represents a risk or defensive aspect for developing hyperinflammatory problems [1, 3, 4, 23, 24]. Released COVID-19-related recommendations offering clinical assistance for the administration of BFH772 kids and children [25C31] are generally predicated on case series, retrospective cohort research, pathophysiological factors, or derive from data on adult populations. As low-quality proof and professional opinion prevail, constant inter-collegial debate facilitate scientific decision making. Right here, we present outcomes of an on the web opinion poll among worldwide pediatric rheumatologists on: (a) feasible general therapy principles in COVID-19 in kids and children and (b) scientific administration of pediatric sufferers with AID-receiving immunomodulation treatment in the framework of SARS-CoV-2 pandemic. Strategies The study collecting opinions inside the worldwide pediatric rheumatology community was executed based on the published tips for survey-based analysis [32]. Pediatric rheumatology specialists (1849 exclusive email addresses), clients to the worldwide on the web Pediatric Rheumatology Bulletin Plank implemented at McMaster School in Canada (https://mailman.mcmaster.ca/mailman/listinfo/ped-rhe-list), were invited to take part in the study via a contact distribution list. The study type was place using SurveyMonkey ? (https://www.surveymonkey.com) and was open up for response from Might 28 to June 11, 2020. The involvement was voluntary, no bonuses were utilized. One reminder email was distributed. The precise wording of the web study form is offered by Supplementary Amount S1. Data on respondents establishments, their knowledge in BFH772 pediatric rheumatology (in years) and their working experience with the treatment of COVID-19 sufferers were gathered. Respondents could express their readiness to consider usage of (off-label) therapies in COVID-19-affected situations. A summary of recommended drugs (find Fig.?1) was provided in BFH772 alphabetical purchase. Potential treatment options were designed for in-patients stratified by COVID-19 disease intensity: Open up in another screen Fig. 1 Therapeutics regarded for pediatric COVID-19. The real variety of respondents expressing their opinion.